Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA + FOLFOX4 second-line treatment for advanced hepatocellular carcinoma with extrahepatic metastasis
ChiCTR2300075615Phase 2Recruiting
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Aug 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tretinoin, oxaliplatin, fluorouracil and folinic acid in hepatocellular carcinoma (HCC), sponsored by Eastern Hepatobiliary Surgery Hospital. Primary endpoint: overall survival. Started Aug 2023; status: recruiting.
02
Drugs
tretinoinoxaliplatinfluorouracilfolinic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300075615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075615.